These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 21298351

  • 21. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC).
    Stoehlmacher-Williams J, Obermann L, Ehninger G, Goekkurt E.
    Anticancer Res; 2012 Feb; 32(2):421-5. PubMed ID: 22287728
    [Abstract] [Full Text] [Related]

  • 22. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
    Yamamoto Y, Yamai H, Seike J, Yoshida T, Takechi H, Furukita Y, Kajiura K, Minato T, Bando Y, Tangoku A.
    Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
    [Abstract] [Full Text] [Related]

  • 23. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Weiner LM, Colarusso P, Goldberg M, Dresler C, Coia LR.
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
    [Abstract] [Full Text] [Related]

  • 24. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
    Lyu X, Huang J, Mao Y, Liu Y, Feng Q, Shao K, Gao S, Jiang Y, Wang J, He J.
    J Surg Oncol; 2014 Dec; 110(7):864-8. PubMed ID: 24976079
    [Abstract] [Full Text] [Related]

  • 25. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.
    Yamasaki M, Miyata H, Fujiwara Y, Takiguchi S, Nakajima K, Nishida T, Yasuda T, Matsuyama J, Mori M, Doki Y.
    Ann Surg Oncol; 2010 Feb; 17(2):634-42. PubMed ID: 19941080
    [Abstract] [Full Text] [Related]

  • 26. Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy.
    Pérez-Regadera J, Sánchez-Muñoz A, De-la-Cruz J, Ballestín C, Lora D, García-Martín R, Sotoca A, Pérez-Ruiz E, Lanzós E.
    Am J Clin Oncol; 2011 Aug; 34(4):395-400. PubMed ID: 20859196
    [Abstract] [Full Text] [Related]

  • 27. Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus.
    Uno T, Isobe K, Kawakami H, Ueno N, Shimada H, Matsubara H, Okazumi S, Nabeya Y, Shiratori T, Kawata T, Ochiai T, Ito H.
    Dis Esophagus; 2007 Aug; 20(1):12-8. PubMed ID: 17227304
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy.
    Hirst J, Smithers BM, Gotley DC, Thomas J, Barbour A.
    Ann Surg Oncol; 2011 Jun; 18(6):1766-74. PubMed ID: 21213056
    [Abstract] [Full Text] [Related]

  • 31. High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
    Kajiwara T, Nishina T, Hyodo I, Moriwaki T, Endo S, Nasu J, Hori S, Matsuura B, Hiasa Y, Onji M.
    Oncology; 2009 Jun; 76(5):342-9. PubMed ID: 19307741
    [Abstract] [Full Text] [Related]

  • 32. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
    Sakaeda T, Yamamori M, Kuwahara A, Hiroe S, Nakamura T, Okumura K, Okuno T, Miki I, Chayahara N, Okamura N, Tamura T.
    Ther Drug Monit; 2008 Aug; 30(4):497-503. PubMed ID: 18641541
    [Abstract] [Full Text] [Related]

  • 33. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Xi H, Baldus SE, Warnecke-Eberz U, Brabender J, Neiss S, Metzger R, Ling FC, Dienes HP, Bollschweiler E, Moenig S, Mueller RP, Hoelscher AH, Schneider PM.
    Clin Cancer Res; 2005 Dec 01; 11(23):8341-7. PubMed ID: 16322294
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials.
    Sohal DP, Rice TW, Rybicki LA, Rodriguez CP, Videtic GM, Saxton JP, Murthy SC, Mason DP, Phillips BE, Tubbs RR, Plesec T, McNamara MJ, Ives DI, Bodmann JW, Adelstein DJ.
    Dis Esophagus; 2015 Dec 01; 28(6):547-51. PubMed ID: 24849395
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.